Early Natalizumab Treatment for First Signs of Multiple Sclerosis
Tests natalizumab shortly after first symptoms in adults with possible or confirmed multiple sclerosis.
Plain-language title generated from the registry record
Registry title: Natalizumab for the Treatment of People With Inflammatory Demyelination Suggestive of Multiple Sclerosis, or Definite Multiple Sclerosis, at First Presentation (AttackMS)
Key facts
- Where
- London, United KingdomSee the 2 sites
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 55 years old?
Source: NCT05418010, who can take part
Where in United Kingdom
- Royal London HospitalLondon, United KingdomNot yet recruiting
- St. George's HospitalLondon, United KingdomTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Queen Mary University of London
- Trial code
- NCT05418010
- Record updated
- 7 January 2026
- Original description
Multiple Sclerosis (MS) is a chronic inflammatory \& degenerative disease of the central nervous system (CNS) Recent data from the MS Base registry demonstrated an average delay of 152 - 215 days between first presentation and the diagnosis of MS, and more than one year until Disease Modifying Treatment (DMT) begins.Read full original descriptionShow less
AttackMS: Natalizumab for the Treatment of People With Inflammatory Demyelination Suggestive of Multiple Sclerosis, or Definite Multiple Sclerosis, at First Presentation
Multiple Sclerosis (MS) is a chronic inflammatory \& degenerative disease of the central nervous system (CNS) Recent data from the MS Base registry demonstrated an average delay of 152 - 215 days between first presentation and the diagnosis of MS, and more than one year until Disease Modifying Treatment (DMT) begins.
Evidence suggests that shutting down inflammation using highly effective DMTs early after diagnosis leads to better long term clinical outcomes The AttackMS trial will test the effect of starting a highly-effective DMT licensed for MS, Tyruko® (Natalizumab 300mg), within a short time - 14 days - after symptom onset.
Inclusion: Participant has provided informed consent; Age 18-55 years; Participant with CIS or MS at first presentation; Participants show two or more lesions on T2 weighted MRI suggestive of demyelination; Participant is willing and able to comply with clinical visits and procedures outlined in the study protocol.
Exclusion: Participants with increased risk for opportunistic infections, including immunocompromised participants (those currently receiving immunosuppressive therapies or those immunocompromised by prior therapies); Combination with other Disease Modifying Treatments; Known active malignancies, except for participants with cutaneous basal cell carcinoma; Implants such as pacemaker, aneurysm clip in the brain and MRI-incompatible prosthetic heart valves; Significant comorbidities such as cardiac failure, renal failure, uncontrolled diabetes and uncontrolled hypercholesterolemia; History of stroke, thrombosis and/or myocardial infarction; Any other infection deemed, in the assessment of the PI or sub-investigator, clinically significant; Hypersensitivity to Tyruko® or to any of the following excipients:; Histidine; Histidine monohydrochloride; Sodium chloride; Polysorbate 80 (E433); Water for injections; Evidence of multiple chronic demyelinating lesions on MRI without signs of recent activity; Claustrophobia; Pregnancy or breastfeeding.